Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
CNS myelin wrapping is driven by actin disassembly.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Food and Drug Administration Approval Letter for Alemtuzumab
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.

Pages